References

vtio

Вестник трансплантологии и искусственных органов

Russian Journal of Transplantology and Artificial Organs

1995-1191

Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation

10.15825/1995-1191-2013-2-142-147

vtio-126

Research Article

Обзор литературы

Literature Reviews

МЕХАНИЗМЫ НЕЛИПИДНОГО ДЕЙСТВИЯ СТАТИНОВ У РЕЦИПИЕНТОВ СЕРДЦА

NON-LIPID MECHANISMS OF STATINS ACTION FOR HEART TRANSPLANT RECIPIENTS

Шевченко

А. О.

Shevchenko

А. О.

Халилулин

Т. А.

Khalilulin

T. A.

Шевченко

О. П.

Shevchenko

O. P.

Кафедра кардиологии ФУВ (зав. – проф. О.П. Шевченко) Российский национальный исследовательский медицинский университет имени Н.И. Пирогова Минздрава России (ректор – проф. А.Г. Камкин), Москва, Российская Федерация ФГБУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России (директор – академик РАМН, проф. С.В. Готье), Москва, Российская ФедерацияDepartment of cardiology (FPU) (Head – Prof. O.P. Shevchenko) Pirogov Russian National Research Medical University (Rector – Prof. A.G. Kamkin), Moscow, Russian Federation Academician V.I. Schumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of the Russian Federation (Head – academician of RAMSci, prof. S.V. Gautier) Moscow, Russian Federation

ФГБУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России (директор – академик РАМН, проф. С.В. Готье), Москва, Российская Федерация Кафедра трансплантологии и искусственных органов (зав. – академик РАМН, проф. С.В. Готье) ГБОУ ВПО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (ректор – член-корреспондент РАМН, проф. П.В. Глыбочко), Москва, Российская ФедерацияAcademician V.I. Schumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of the Russian Federation (Head – academician of RAMSci, prof. S.V. Gautier) Moscow, Russian Federation Department of Transplantation and Artificial Organs (Head – academician of RAMSci, prof. S.V. Gauthier) First Moscow State Medical University named after I.M. Sechenov (Rector – corresponding member of RAMSci, prof. P.V. Glybochko), Moscow, Russian Federation

ФГБУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России (директор – академик РАМН, проф. С.В. Готье), Москва, Российская ФедерацияAcademician V.I. Schumakov Federal Research Center of Transplantology and Artificial Organs, Ministry of Health of the Russian Federation (Head – academician of RAMSci, prof. S.V. Gautier) Moscow, Russian Federation

2013

26052014

152

ВЕСТНИК ТРАНСПЛАНТОЛОГИИ И ИСКУССТВЕННЫХ ОРГАНОВ том XV No 2–2013

142147

2013

Шевченко А.О., Халилулин Т.А., Шевченко О.П.

Shevchenko А.О., Khalilulin T.A., Shevchenko O.P.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.transpl.ru/vtio/article/view/126

Статины широко используются при лечении реципиентов с пересаженным сердцем. Предполагается, что эффективность применения статинов после трансплантации сердца обусловлена не только гиполипиде- мическим, но и нелипидными, в том числе противовоспалительным, эффектами. В обзоре представлены опубликованные в последнее время результаты про- и ретроспективных исследований роли статинов в посттрансплантационной терапии реципиентов пересаженного сердца. Проанализированы иммуномоду- лирующие и противовоспалительные механизмы, основанные на снижении уровня С-реактивного белка, уменьшении концентрации цитокинов (ФНО-α, ИЛ-6, ИЛ-2Р), подавлении экспрессии тканевого фактора моноцитами и др. Немаловажна роль статинов в снижении риска развития онкологических заболеваний у реципиентов. Применение статинов в комплексной терапии с иммуносупрессантами является важным фактором оптимизации отдаленных результатов, уменьшения частоты развития острого отторжения и болезни коронарных артерий пересаженного сердца, увеличения длительности и улучшения качества жизни реципиентов с пересаженным сердцем.

Statins are widely used in the treatment of heart transplant recipients. It is assumed that the effectiveness of statins after heart transplantation is due not only to hypolipidemic effects, but also to non-lipid effects, including anti-inflammato- ry. In the review are presented the recently published results of the pro-and retrospective studies on the role of statins in the treatment of post-heart transplant recipients. Also there were analyzed the immunomodulatory and anti-in- flammatory mechanisms based on reduced levels of C-reactive protein, decreased concentration of cytokines (TNF-α, IL-6, IL-2R), suppression of tissue factor expression by monocytes etc. Another important factor is the role of statins in reducing the risk of cancer for transplant recipients. The use of statins in the treatment with immunosuppressive agents is an important factor in optimizing the long-term outcomes, reduction in the incidence of acute rejection and coronary artery disease of transplanted heart, increasing the duration and quality of life for heart transplant recipients.

трансплантация сердцастатиныиммуносупрессияболезнь коронарных артерий пересаженного сердца

heart transplantationstatinsimmunosupressioncoronary artery disease

References1

Mehra M.R. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy // Am. J. Transplant. 2006; 6: 1248–1256.

Rahmani M., Cruz R.P., Granville D.J., McManus B.M. Allograft vasculopathy versus atherosclerosis // Circ. Res. 2006; 99: 801–815.

Kobashigawa J.A. Statins and cardiac allograft vascu- lopathy after heart transplantation // Sem. Vasc. Med. 2004; 4: 401–406.

Segovia J., Gomez-Bueno M., Alonso-Pulpon L. Treat- ment of allograft vasculopathy in heart transplantation // Expert Opin Pharmacother. 2006; 7: 2369–2383.

Cutts J.L., Scallen T.J., Watson J., Bankhurst A.D. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity // J. Cell. Physiol. 1989; 139: 550–557.

Meiser B.M., Wenke K., Thiery J. Simvastatin decreases accelerated graft vessel disease after heart transplanta- tion in an animal model // Transplant. Proc. 1993; 25: 2077–2079.

Ogawa N., Koyama I., Shibata T. Pravastatin prevents the progression of accelerated coronary artery disease af- ter heart transplantation in a rabbit model // Transplant. Int. 1996; 9. S226–229.

Kobashigawa J.A., Katznelson S., Laks H. Effect of pra- vastatin on outcomes after cardiac transplantation // N. Engl. J. Med. 1995; 333: 621–627.

Wenke K., Meiser B., Thiery J. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial // Circulation. 1997; 96: 1398–1402.

Kato T., Tokoro T., Namii Y. Early introduction of HMG- CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease // Transplant. Proc. 2000; 32: 331–333.

Holschermann H., Hilgendorff A., Kemkes-Matthes B. Simvastatin attenuates vascular hypercoagulability in cardiac transplant patients // Transplantation. 2000; 69: 1830–1836.

Mehra M.R., Uber P.A., Vivekananthan K. Comparative beneficial effects of simvastatin and pravastatin on cardi- ac allograft rejection and survival // J. Am. Coll. Cardiol. 2002; 40: 1609–1614.

Wenke K., Meiser B., Thiery J. Simvastatin initiated ear- ly after heart transplantation: 8-year prospective experi- ence // Circulation. 2003; 107: 93–97.

Wenke K., Meiser B., Thiery J., Reichart B. Impact of simvastatin therapy after heart transplantation: an

-year prospective evaluation // Herz. 2005; 30: 431–

See Jr V.Y., DeNofrio D., Goldberg L. Effect of atorvas-

tatin on post- cardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction // Am. J. Cardiol. 2003; 92: 11–15.

O'Rourke B., Barbir M., Mitchell A.G. Efficacy and sa- fety of fluvastatin therapy for hypercholesterolemia af- ter heart transplantation: results of a randomised double blind placebo controlled study // Int. J. Cardiol. 2004; 94: 235–240.

WuA.H.,BallantyneC.M.,ShortB.C.Statinuseandrisks of death or fatal rejection in the Heart Transplant Lipid Registry // Am. J. Cardiol. 2005; 95: 367–372.

Stojanovic I., Vrtovec B., Radovancevic B. Survival, graft atherosclerosis, and rejection incidence in heart transplant recipients treated with statins: 5-year follow- up // J. Heart Lung Transplant. 2005; 24: 1235–1238.

Lubitz S.A., Baran D.A., Alwarshetty M.M. Improved survival with statins, angiotensin receptor blockers, and steroid weaning after heart transplantation // Transplant. Proc. 2006; 38: 1501–1506.

Tona F., Marra M.P., Fedrigo M. Recent developments on coronary microvasculopathy after heart transplan- tation: a new target in the therapy of cardiac allograft vasculopathy // Curr. Vasc. Pharmacol. 2012; 10 (2): 206–215.

Шевченко О.П., Шевченко А.О. Статины. Ингибито- ры ГМГ–КоА редуктазы. М.: Реафарм, 2003: 112. Shevchenko O.P., Shevchenko А.О. Statins. HMG-CoA reductase inhibitors. M.: Reafarm, 2003: 112.

Hognestad A., Endresen K., Wergeland R. Plasma C-re- active protein as a marker of cardiac allograft vasculopa- thy in heart transplant recipients // J. Am. Coll Cardiol. 2003; 42: 477–482.

Ventura H.O., Mehra M.R. C-reactive protein and car- diac allograft vasculopathy: is inflammation the critical link? // J. Am. Coll Cardiol. 2003; 42: 483–485.

Weis M., Pehlivanli S., Meiser B.M., von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation // J. Am. Coll Cardiol. 2001; 38: 814–818.

Wallace C.K., Stetson S.J., Kucuker S.A. Simvastatin de- creases myocardial tumor necrosis factor alpha content in heart transplant recipients // J. Heart. Lung Transplant. 2005; 24: 46–51.

Simeoni E., Dudler J., Fleury S. Gene transfer of a solub- le IL-1 type 2 receptor-Ig fusion protein improves cardi- ac allograft survival in rats // Eur. J. Cardiothorac. Surg. 2007; 32: 90–95.

Holm T., Andreassen A.K., Ueland T. Effect of pravas- tatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients // Am. J. Cardiol. 2001; 87: 815–818.

Holschermann H., Hilgendorff A., Kemkes-Matthes B. Simvastatin attenuates vascular hypercoagulability in cardiac transplant patients // Transplantation. 2000; 69: 1830–1836.

Jenkins G.H., Grieve L.A., Yacoub M.H., Singer D.R. Effect of simvastatin on ejection fraction in cardiac transplant recipients // Am. J. Cardiol. 1996; 78: 1453– 1456.

Lubitz S.A., Pinney S., Wisnivesky J.P. Statin therapy as- sociated with a reduced risk of chronic renal failure af- ter cardiac transplantation // J. Heart. Lung Transplant. 2007; 26: 264–272.

Aharinejad S., Krenn K., Zuckermann A. Matrix metal- loproteinases and their tissue inhibitor in cardiac trans- plantation // Eur. J. Cardiothorac Surg. 2007; 32: 48–51.

Suzuki J., Isobe M., Kawauchi M. Altered expression of matrix metalloproteinases and tissue inhibitors of metal- loproteinases in acutely rejected myocardium and coro- nary arteriosclerosis in cardiac allografts of nonhuman primates // Transplant. Int. 2000; 13: 106–113.

Furman C., Copin C., Kandoussi M. Rosuvastatin reduc- es MMP-7 secretion by human monocyte-derived mac- rophages: potential relevance to atherosclerotic plaque stability // Atherosclerosis. 2004; 174: 93–98.

Stein W., Schrepfwer S., Iton S. Prevention of trans- plant coronary artery disease by prenylation inhibitors // J. Heart. Lung Transplant. 2011; 30: 761–769.

Grauhan O., Siniawski H., Dandel M. Coronary athero- sclerosis of the donor heart – impact on early graft fail- ure // Eur. J. Cardiothorac. Surg. 2007; 32: 634–638.

Nissen S.E., Nicholls S.J., Sipahi I. Effect of very high- intensity statin therapy on regression of coronary ath- erosclerosis: the ASTEROID trial. JAMA. 2006; 295. 1556–1565.

Sipahi I., Nicholls S.J., Tuzcu E.M., Nissen S.E. Coro- nary atherosclerosis can regress with very intensive statin therapy // Cleve Clin. J. Med. 2006; 73: 937–944.

Shirakawa I., Sata M., Saiura A. Atorvastatin attenua- tes transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation // Biomed Phar- macother. 2007; 61: 154–159.

Mehra M.R., Raval N.Y. Metaanalysis of statins and sur- vival in de novo cardiac transplantation // Transplant. Proc. 2004; 36: 1539–1541.

Kobashigawa J.A., Moriguchi J.D., Laks H. Ten-year follow- up of a randomized trial of pravastatin in heart transplant patients // J. Heart. Lung Transplant. 2005; 24: 1736–1740.

Abu-Qaoud M.S., Stoletniy L.N., Chen D. Lack of re- lationship between microvascular and macrovascular

disease in heart transplant recipients // Transplantation.

; 94 (9): 965–970.

Gazi I.F., Liberopoulos E.N., Athyros V.G., Mikhaili-

dis D.P. Statins and solid organ transplantation // Curr.

Pharm. Des. 2006; 12: 4771–4783.

Fröhlich G.M., Rufibach K., Enseleit F. Statins and the

risk of cancer after heart transplantation // Circulation.

; 126 (4): 440–447.

Clarke N.W., Brown M.D. Should All Patients Receive

Statins to Reduce Cancer Risk After Heart Transplanta-

tion? // Circulation. 2012; 126 (4): 391–391.

Zakliczynski M., Boguslawska J., Wojniak E. In the era of the universal use of statins dyslipidemia's are still common in heart transplant recipients: a cross-sectional

study // Transplant. Proc. 2011; 43 (8): 3071–3073.

Mahle W.T., Vincent R.N., Berg A.M., Kanter K.R. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation // J. Heart. Lung Transplant. 2005; 24:

–66.

Seipelt I.M., Crawford S.E., Rodgers S. Hypercholeste-

rolemia is common after pediatric heart transplantati- on: initial experience with pravastatin // J. Heart. Lung Transplant. 2004; 23: 317–322.

de Denus S., Al-Jazairi A., Loh E. Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients // Ann. Pharmacother. 2004; 38: 1136–1141.

Kato T., Tokoro T., Namii Y. Early introduction of HMG- CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease // Transplant. Proc. 2000; 32: 331–333.

O'Rourke B., Barbir M., Mitchell A.G. Efficacy and safe- ty of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study // Int. J. Cardiol. 2004; 94: 235–240.

See Jr V.Y., DeNofrio D., Goldberg L. Effect of atorvas- tatin on post-cardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction // Am. J. Cardiol. 2003; 92: 11–15.

Lubitz S.A., Baran D.A., Alwarshetty M.M. Improved survival with statins, angiotensin receptor blockers, and steroid weaning after heart transplantation // Transplant. Proc. 2006; 38: 1501–1506.

The authors declare that there are no conflicts of interest present.